메뉴 건너뛰기




Volumn 6, Issue 1, 2016, Pages 39-54

Brexpiprazole: so far so good

Author keywords

antipsychotic; brexpiprazole; major depressive disorder; schizophrenia

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; CHLORPROMAZINE; PLACEBO;

EID: 84996539260     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125315614739     Document Type: Review
Times cited : (58)

References (103)
  • 1
    • 3142739323 scopus 로고    scopus 로고
    • Adrenergic targets for the treatment of cognitive deficits in schizophrenia
    • A.Arnsten (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl)174: 25–31.
    • (2004) Psychopharmacology (Berl) , vol.174 , pp. 25-31
    • Arnsten, A.1
  • 3
    • 0032007608 scopus 로고    scopus 로고
    • Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
    • J.ArntT.Skarsfeldt (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology18: 63–101.
    • (1998) Neuropsychopharmacology , vol.18 , pp. 63-101
    • Arnt, J.1    Skarsfeldt, T.2
  • 4
    • 0034745153 scopus 로고    scopus 로고
    • The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
    • R.BantickJ.DeakinP.Grasby (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?J Psychopharmacol15: 37–46.
    • (2001) J Psychopharmacol , vol.15 , pp. 37-46
    • Bantick, R.1    Deakin, J.2    Grasby, P.3
  • 5
    • 0024358369 scopus 로고
    • A rating scale for drug-induced akathisia
    • T.Barnes (1989) A rating scale for drug-induced akathisia. Br J Psychiatry154: 672–676.
    • (1989) Br J Psychiatry , vol.154 , pp. 672-676
    • Barnes, T.1
  • 6
    • 29344438343 scopus 로고    scopus 로고
    • Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety
    • P.BlierS.Szabo (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry66(Suppl. 8): 30–40.
    • (2005) J Clin Psychiatry , vol.66 , pp. 30-40
    • Blier, P.1    Szabo, S.2
  • 8
    • 84896715449 scopus 로고    scopus 로고
    • α2-adrenoceptors are targets for antipsychotic drugs
    • J.BrosdaF.JantschakH.Pertz (2014) α2-adrenoceptors are targets for antipsychotic drugs. Psychopharmacology231: 801–812.
    • (2014) Psychopharmacology , vol.231 , pp. 801-812
    • Brosda, J.1    Jantschak, F.2    Pertz, H.3
  • 9
    • 0036089687 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    • K.BurrisT.MolskiC.XuE.RyanK.TottoriT.Kikuchi. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther302: 381–389.
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 381-389
    • Burris, K.1    Molski, T.2    Xu, C.3    Ryan, E.4    Tottori, K.5    Kikuchi, T.6
  • 10
    • 10544243792 scopus 로고    scopus 로고
    • Side effect profiles of new antipsychotic agents
    • discussion 46–52
    • D.Casey (1996) Side effect profiles of new antipsychotic agents. J Clin Psychiatry57(Suppl. 11): 40–45, discussion 46–52.
    • (1996) J Clin Psychiatry , vol.57 , pp. 40-45
    • Casey, D.1
  • 11
    • 51849168937 scopus 로고    scopus 로고
    • Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
    • D.CaseyE.SandsJ.HeisterbergH.Yang (2008) Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl)200: 317–331.
    • (2008) Psychopharmacology (Berl) , vol.200 , pp. 317-331
    • Casey, D.1    Sands, E.2    Heisterberg, J.3    Yang, H.4
  • 12
    • 84872473680 scopus 로고    scopus 로고
    • Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
    • L.Citrome (2013) Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol9: 193–206.
    • (2013) Expert Opin Drug Metab Toxicol , vol.9 , pp. 193-206
    • Citrome, L.1
  • 13
    • 84940448621 scopus 로고    scopus 로고
    • Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    • L.Citrome (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract69: 978–997.
    • (2015) Int J Clin Pract , vol.69 , pp. 978-997
    • Citrome, L.1
  • 14
    • 77954166205 scopus 로고    scopus 로고
    • From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics
    • C.Correll (2010) From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry25(Suppl. 2): S12–S21.
    • (2010) Eur Psychiatry , vol.25 , pp. 12-21
    • Correll, C.1
  • 15
    • 84915755691 scopus 로고    scopus 로고
    • Cardio metabolic risk in first episode schizophrenia-spectrum disorder patients: baseline results from the RAISE-ETP study
    • C.CorrellD.RobinsonN.SchoolerM.BrunetteK.MueserR.Rosenheck. (2014) Cardio metabolic risk in first episode schizophrenia-spectrum disorder patients: baseline results from the RAISE-ETP study. JAMA Psychiatry71: 1350–1363.
    • (2014) JAMA Psychiatry , vol.71 , pp. 1350-1363
    • Correll, C.1    Robinson, D.2    Schooler, N.3    Brunette, M.4    Mueser, K.5    Rosenheck, R.6
  • 16
    • 84937234454 scopus 로고    scopus 로고
    • Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial
    • C.CorrellA.SkubanJ.OuyangM.HobartS.PfisterR.McQuade. (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry172: 870–880.
    • (2015) Am J Psychiatry , vol.172 , pp. 870-880
    • Correll, C.1    Skuban, A.2    Ouyang, J.3    Hobart, M.4    Pfister, S.5    McQuade, R.6
  • 17
    • 58149469090 scopus 로고    scopus 로고
    • Translational control of long lasting synaptic plasticity and memory
    • M.Costa-MattioliW.SossinE.KlannN.Sonenberg (2009) Translational control of long lasting synaptic plasticity and memory. Neuron61: 10–26.
    • (2009) Neuron , vol.61 , pp. 10-26
    • Costa-Mattioli, M.1    Sossin, W.2    Klann, E.3    Sonenberg, N.4
  • 18
    • 3142737856 scopus 로고    scopus 로고
    • The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
    • J.CoyleG.Tsai (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl)174: 32–38.
    • (2004) Psychopharmacology (Berl) , vol.174 , pp. 32-38
    • Coyle, J.1    Tsai, G.2
  • 19
    • 62149121073 scopus 로고    scopus 로고
    • Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour
    • L.DahanH.HusumO.Mnie-FilaliJ.ArntP.HertelN.Haddjeri (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol23: 177–189.
    • (2009) J Psychopharmacol , vol.23 , pp. 177-189
    • Dahan, L.1    Husum, H.2    Mnie-Filali, O.3    Arnt, J.4    Hertel, P.5    Haddjeri, N.6
  • 20
    • 84856466929 scopus 로고    scopus 로고
    • Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
    • M.De HertJ.DetrauxR.van WinkelW.YuC.Correll (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol8: 114–126.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 114-126
    • De Hert, M.1    Detraux, J.2    van Winkel, R.3    Yu, W.4    Correll, C.5
  • 21
    • 84903179140 scopus 로고    scopus 로고
    • Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats
    • M.De SantisB.PanJ.LianX.HuangC.Deng (2014) Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav124: 167–173.
    • (2014) Pharmacol Biochem Behav , vol.124 , pp. 167-173
    • De Santis, M.1    Pan, B.2    Lian, J.3    Huang, X.4    Deng, C.5
  • 22
    • 0036550282 scopus 로고    scopus 로고
    • Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates
    • C.DrouinL.DarracqF.TroveroG.BlancJ.GlowinskiS.Cotecchia. (2002) Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci22: 2873–2884.
    • (2002) J Neurosci , vol.22 , pp. 2873-2884
    • Drouin, C.1    Darracq, L.2    Trovero, F.3    Blanc, G.4    Glowinski, J.5    Cotecchia, S.6
  • 23
    • 84862156355 scopus 로고    scopus 로고
    • Initial validity and reliability data on the Columbia-Suicide Severity Rating Scale
    • author reply 663
    • P.ChappellD.FeltnerC.MakumiM.Stewart (2012) Initial validity and reliability data on the Columbia-Suicide Severity Rating Scale. Am J Psychiatry169: 662–663; author reply 663.
    • (2012) Am J Psychiatry , vol.169 , pp. 662-663
    • Chappell, P.1    Feltner, D.2    Makumi, C.3    Stewart, M.4
  • 25
    • 0032414602 scopus 로고    scopus 로고
    • Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression
    • J.FawcettR.Barkin (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord51: 267–285.
    • (1998) J Affect Disord , vol.51 , pp. 267-285
    • Fawcett, J.1    Barkin, R.2
  • 27
    • 0142244688 scopus 로고    scopus 로고
    • Schizophrenia
    • R.Freedman (2003) Schizophrenia. N Engl J Med349: 1738–1749.
    • (2003) N Engl J Med , vol.349 , pp. 1738-1749
    • Freedman, R.1
  • 28
    • 37349093431 scopus 로고    scopus 로고
    • The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long acting injectable
    • G.GharabawiC.BossieI.TurkozM.KujawaR.MahmoudG.Simpson (2007) The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long acting injectable. J Nerv Ment Dis195: 976–982.
    • (2007) J Nerv Ment Dis , vol.195 , pp. 976-982
    • Gharabawi, G.1    Bossie, C.2    Turkoz, I.3    Kujawa, M.4    Mahmoud, R.5    Simpson, G.6
  • 29
    • 84941126254 scopus 로고    scopus 로고
    • Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole
    • D.Goff (2015) Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole. Am J Psychiatry172: 820–821.
    • (2015) Am J Psychiatry , vol.172 , pp. 820-821
    • Goff, D.1
  • 30
    • 0029918481 scopus 로고    scopus 로고
    • What are the functional consequences of neurocognitive deficits in schizophrenia?
    • M.Green (1996) What are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry153: 321–330.
    • (1996) Am J Psychiatry , vol.153 , pp. 321-330
    • Green, M.1
  • 31
    • 4444220908 scopus 로고    scopus 로고
    • Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
    • M.GreenK.NuechterleinJ.GoldD.BarchJ.CohenS.Essock. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry56: 301–307.
    • (2004) Biol Psychiatry , vol.56 , pp. 301-307
    • Green, M.1    Nuechterlein, K.2    Gold, J.3    Barch, D.4    Cohen, J.5    Essock, S.6
  • 32
    • 84868311517 scopus 로고    scopus 로고
    • The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions
    • G.GrossK.Drescher (2012) The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol213: 167–210.
    • (2012) Handb Exp Pharmacol , vol.213 , pp. 167-210
    • Gross, G.1    Drescher, K.2
  • 33
    • 0003412410 scopus 로고
    • Rockville, MD: National Institute of Mental Health,, (ed) (,. US Department of Health, Education and Welfare Publication (ADM)
    • W.Guy (ed) (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health.
    • (1976) ECDEU Assessment Manual for Psychopharmacology , pp. 76-338
    • Guy, W.1
  • 34
    • 0030431697 scopus 로고    scopus 로고
    • Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain
    • N.HaddjeriP.BlierC.de Montigny (1996) Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther277: 861–871.
    • (1996) J Pharmacol Exp Ther , vol.277 , pp. 861-871
    • Haddjeri, N.1    Blier, P.2    de Montigny, C.3
  • 35
    • 42749092601 scopus 로고    scopus 로고
    • Phencyclidine induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor
    • H.HagiwaraY.FujitaT.IshimaS.KunitachiY.ShirayamaM.Iyo. (2008) Phencyclidine induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor. Eur Neuropsychopharmacol18: 448–454.
    • (2008) Eur Neuropsychopharmacol , vol.18 , pp. 448-454
    • Hagiwara, H.1    Fujita, Y.2    Ishima, T.3    Kunitachi, S.4    Shirayama, Y.5    Iyo, M.6
  • 36
    • 33748455912 scopus 로고    scopus 로고
    • The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs
    • K.Hashimoto (2006) The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci4: 3–10.
    • (2006) Clin Psychopharmacol Neurosci , vol.4 , pp. 3-10
    • Hashimoto, K.1
  • 37
    • 84906228003 scopus 로고    scopus 로고
    • Targeting of NMDA receptors in new treatments for schizophrenia
    • K.Hashimoto (2014) Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets18: 1049–1063.
    • (2014) Expert Opin Ther Targets , vol.18 , pp. 1049-1063
    • Hashimoto, K.1
  • 38
    • 27744572308 scopus 로고    scopus 로고
    • Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol
    • K.HashimotoY.FujitaE.ShimizuM.Iyo (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol519: 114–117.
    • (2005) Eur J Pharmacol , vol.519 , pp. 114-117
    • Hashimoto, K.1    Fujita, Y.2    Shimizu, E.3    Iyo, M.4
  • 39
    • 78149472832 scopus 로고    scopus 로고
    • A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI
    • K.HashimotoT.Ishima (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI. PLoS ONE5: e15430.
    • (2010) PLoS ONE , vol.5 , pp. 15430
    • Hashimoto, K.1    Ishima, T.2
  • 40
    • 79952285928 scopus 로고    scopus 로고
    • Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol
    • K.HashimotoT.Ishima (2011) Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol. PLoS One6: e17431.
    • (2011) PLoS One , vol.6 , pp. 17431
    • Hashimoto, K.1    Ishima, T.2
  • 41
    • 84881313914 scopus 로고    scopus 로고
    • Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
    • K.HashimotoB.MalchowP.FalkaiA.Schmitt (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci263: 367–377.
    • (2013) Eur Arch Psychiatry Clin Neurosci , vol.263 , pp. 367-377
    • Hashimoto, K.1    Malchow, B.2    Falkai, P.3    Schmitt, A.4
  • 42
    • 84937714818 scopus 로고    scopus 로고
    • Brexpiprazole: another multipurpose antipsychotic drug?
    • R.Howland (2015) Brexpiprazole: another multipurpose antipsychotic drug?J Psychosoc Nurs Ment Health Serv53: 23–25.
    • (2015) J Psychosoc Nurs Ment Health Serv , vol.53 , pp. 23-25
    • Howland, R.1
  • 43
    • 0037239089 scopus 로고    scopus 로고
    • Extra pyramidal symptom profiles assessed with the Drug-Induced Extra pyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
    • T.InadaC.BeasleyY.TanakaD.Walker (2003) Extra pyramidal symptom profiles assessed with the Drug-Induced Extra pyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol18: 39–48.
    • (2003) Int Clin Psychopharmacol , vol.18 , pp. 39-48
    • Inada, T.1    Beasley, C.2    Tanaka, Y.3    Walker, D.4
  • 44
    • 84928212338 scopus 로고    scopus 로고
    • Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors
    • T.IshimaT.FutamuraY.OhgiN.YoshimiT.KikuchiK.Hashimoto (2015) Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharm25: 505–511.
    • (2015) Eur Neuropsychopharm , vol.25 , pp. 505-511
    • Ishima, T.1    Futamura, T.2    Ohgi, Y.3    Yoshimi, N.4    Kikuchi, T.5    Hashimoto, K.6
  • 45
    • 84861369885 scopus 로고    scopus 로고
    • Potentiation of nerve growth factor induced neurite outgrowth in PC 12 cells by ifenprodil: role of sigma-1and IP3 receptors
    • T.IshimaK.Hashimoto (2012) Potentiation of nerve growth factor induced neurite outgrowth in PC 12 cells by ifenprodil: role of sigma-1and IP3 receptors. PLoS ONE7: e37989.
    • (2012) PLoS ONE , vol.7 , pp. 37989
    • Ishima, T.1    Hashimoto, K.2
  • 46
    • 84873941807 scopus 로고    scopus 로고
    • Neurite outgrowth mediated by the heat shock protein HSP90α: a novel target for the antipsychotic drug aripiprazole
    • T.IshimaM.IyoK.Hashimoto (2012) Neurite outgrowth mediated by the heat shock protein HSP90α: a novel target for the antipsychotic drug aripiprazole. Transl Psychiatry2: e170.
    • (2012) Transl Psychiatry , vol.2 , pp. 170
    • Ishima, T.1    Iyo, M.2    Hashimoto, K.3
  • 47
    • 79951553138 scopus 로고    scopus 로고
    • Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma and IP3 receptors
    • K.ItohT.IshimaJ.KehlerK.Hashimoto (2011) Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma and IP3 receptors. Brain Res1377: 32–40.
    • (2011) Brain Res , vol.1377 , pp. 32-40
    • Itoh, K.1    Ishima, T.2    Kehler, J.3    Hashimoto, K.4
  • 48
    • 84928640856 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
    • J.KaneA.SkubanJ.OuyangM.HobartS.PfisterR.McQuade. (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizphr Res164: 127–135.
    • (2015) Schizphr Res , vol.164 , pp. 127-135
    • Kane, J.1    Skuban, A.2    Ouyang, J.3    Hobart, M.4    Pfister, S.5    McQuade, R.6
  • 50
    • 0029023002 scopus 로고
    • 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity
    • T.KikuchiK.TottoriY.UwahodoT.HiroseT.MiwaY.Oshiro. (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther274: 329–336.
    • (1995) J Pharmacol Exp Ther , vol.274 , pp. 329-336
    • Kikuchi, T.1    Tottori, K.2    Uwahodo, Y.3    Hirose, T.4    Miwa, T.5    Oshiro, Y.6
  • 51
    • 77949701274 scopus 로고    scopus 로고
    • Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist partial agonist antipsychotic candidate: in vitro and neurochemical profile
    • B.KissA.HorváthZ.NémethyE.SchmidtI.LaszlovszkyG.Bugovics. (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther333: 328–340.
    • (2010) J Pharmacol Exp Ther , vol.333 , pp. 328-340
    • Kiss, B.1    Horváth, A.2    Némethy, Z.3    Schmidt, E.4    Laszlovszky, I.5    Bugovics, G.6
  • 52
    • 0030440884 scopus 로고    scopus 로고
    • Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys
    • M.KlevenW.Koek (1996) Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther279: 1211–1219.
    • (1996) J Pharmacol Exp Ther , vol.279 , pp. 1211-1219
    • Kleven, M.1    Koek, W.2
  • 54
    • 50349086333 scopus 로고    scopus 로고
    • Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
    • T.KurokiN.NagaoT.Nakahara (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res172: 199–212.
    • (2008) Prog Brain Res , vol.172 , pp. 199-212
    • Kuroki, T.1    Nagao, N.2    Nakahara, T.3
  • 55
    • 84922079754 scopus 로고    scopus 로고
    • Antipsychotic induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice
    • Z.LaoutidisK.Kioulos (2014) Antipsychotic induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology (Berl)231: 4255–4270.
    • (2014) Psychopharmacology (Berl) , vol.231 , pp. 4255-4270
    • Laoutidis, Z.1    Kioulos, K.2
  • 56
    • 84898057496 scopus 로고    scopus 로고
    • 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis
    • Z.LaoutidisC.Luckhaus (2014) 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol17: 823–832.
    • (2014) Int J Neuropsychopharmacol , vol.17 , pp. 823-832
    • Laoutidis, Z.1    Luckhaus, C.2
  • 57
    • 84884161208 scopus 로고    scopus 로고
    • Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis
    • S.LeuchtA.CiprianiL.SpineliD.MavridisD.OreyF.Richter (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis. Lancet382: 951–962.
    • (2013) Lancet , vol.382 , pp. 951-962
    • Leucht, S.1    Cipriani, A.2    Spineli, L.3    Mavridis, D.4    Orey, D.5    Richter, F.6
  • 58
    • 0035666578 scopus 로고    scopus 로고
    • The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches
    • J.LiebermanD.PerkinsA.BelgerM.ChakosF.JarskogK.Boteva. (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry50: 884–897.
    • (2001) Biol Psychiatry , vol.50 , pp. 884-897
    • Lieberman, J.1    Perkins, D.2    Belger, A.3    Chakos, M.4    Jarskog, F.5    Boteva, K.6
  • 60
    • 84904981694 scopus 로고    scopus 로고
    • Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator
    • K.MaedaL.LerdrupH.SuginoH.AkazawaN.AmadaR.McQuade. (2014a) Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther350: 605–614.
    • (2014) J Pharmacol Exp Ther , vol.350 , pp. 605-614
    • Maeda, K.1    Lerdrup, L.2    Sugino, H.3    Akazawa, H.4    Amada, N.5    McQuade, R.6
  • 61
    • 84903982078 scopus 로고    scopus 로고
    • Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
    • K.MaedaH.SuginoH.AkazawaN.AmadaJ.ShimadaT.Futamura. (2014b) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther350: 589–604.
    • (2014) J Pharmacol Exp Ther , vol.350 , pp. 589-604
    • Maeda, K.1    Sugino, H.2    Akazawa, H.3    Amada, N.4    Shimada, J.5    Futamura, T.6
  • 62
    • 34648830603 scopus 로고    scopus 로고
    • Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study
    • D.MamoA.GraffR.MizrahiC.ShammiF.RomeyerS.Kapur (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry164: 1411–1417.
    • (2007) Am J Psychiatry , vol.164 , pp. 1411-1417
    • Mamo, D.1    Graff, A.2    Mizrahi, R.3    Shammi, C.4    Romeyer, F.5    Kapur, S.6
  • 63
    • 77957241598 scopus 로고    scopus 로고
    • Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission
    • M.MarcusC.WikerO.FrånbergA.Konradsson-GeukenX.LangloisK.Jardemark. (2010) Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol13: 891–903.
    • (2010) Int J Neuropsychopharmacol , vol.13 , pp. 891-903
    • Marcus, M.1    Wiker, C.2    Frånberg, O.3    Konradsson-Geuken, A.4    Langlois, X.5    Jardemark, K.6
  • 64
    • 0031431410 scopus 로고    scopus 로고
    • The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials
    • S.MarderJ.DavisG.Chouinard (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry58: 538–546.
    • (1997) J Clin Psychiatry , vol.58 , pp. 538-546
    • Marder, S.1    Davis, J.2    Chouinard, G.3
  • 65
    • 33747308393 scopus 로고    scopus 로고
    • Serum creatine kinase levels in chronic psychosis patients: a comparison between atypical and conventional antipsychotics
    • K.Melkersson (2006) Serum creatine kinase levels in chronic psychosis patients: a comparison between atypical and conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry30: 1277–1282.
    • (2006) Prog Neuropsychopharmacol Biol Psychiatry , vol.30 , pp. 1277-1282
    • Melkersson, K.1
  • 66
    • 0032868798 scopus 로고    scopus 로고
    • The role of serotonin in antipsychotic drug action
    • H.Meltzer (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology21(2 Suppl.): 106S–115S.
    • (1999) Neuropsychopharmacology , vol.21 , Issue.2 , pp. 106-115
    • Meltzer, H.1
  • 67
    • 84868332431 scopus 로고    scopus 로고
    • Serotonergic mechanisms as targets for existing and novel antipsychotics
    • H.Meltzer (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol212: 87–124.
    • (2012) Handb Exp Pharmacol , vol.212 , pp. 87-124
    • Meltzer, H.1
  • 68
    • 77957751075 scopus 로고    scopus 로고
    • Potentiation of nerve growth factor induced neurite out growth by the ROCK inhibitor Y-27632: a possible role of IP3 receptors
    • T.MinaseT.IshimaK.ItohK.Hashimoto (2010) Potentiation of nerve growth factor induced neurite out growth by the ROCK inhibitor Y-27632: a possible role of IP3 receptors. Eur J Pharmacol648: 67–73.
    • (2010) Eur J Pharmacol , vol.648 , pp. 67-73
    • Minase, T.1    Ishima, T.2    Itoh, K.3    Hashimoto, K.4
  • 69
    • 0027446907 scopus 로고
    • In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenergic receptors on 5-hydroxytryptamine terminals in the rat hippo campus
    • R.MongeauP.BlierC.deMontigny (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenergic receptors on 5-hydroxytryptamine terminals in the rat hippo campus. Naunyn Schmiedebergs Arch Pharmacol347: 266–272.
    • (1993) Naunyn Schmiedebergs Arch Pharmacol , vol.347 , pp. 266-272
    • Mongeau, R.1    Blier, P.2    deMontigny, C.3
  • 70
    • 77954120696 scopus 로고    scopus 로고
    • Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects
    • J.Monti (2010) Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects. Drugs Today (Barc)46: 183–193.
    • (2010) Drugs Today (Barc) , vol.46 , pp. 183-193
    • Monti, J.1
  • 71
    • 79953100409 scopus 로고    scopus 로고
    • Validation of the excited component of the Positive and Negative Syndrome Scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
    • A.MontoyaA.ValladaresL.LizánL.SanR.EscobarS.Paz (2011) Validation of the excited component of the Positive and Negative Syndrome Scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes9: 18.
    • (2011) Health Qual Life Outcomes , vol.9 , pp. 18
    • Montoya, A.1    Valladares, A.2    Lizán, L.3    San, L.4    Escobar, R.5    Paz, S.6
  • 72
    • 69049088714 scopus 로고    scopus 로고
    • Effect of sertindole on extracellular dopamine and glutamate in the frontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved
    • A.MørkL.WittenJ.Arnt (2009) Effect of sertindole on extracellular dopamine and glutamate in the frontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Eur J Pharmacol206: 39–49.
    • (2009) Eur J Pharmacol , vol.206 , pp. 39-49
    • Mørk, A.1    Witten, L.2    Arnt, J.3
  • 73
    • 0034022621 scopus 로고    scopus 로고
    • Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning
    • P.MorosiniL.MaglianoL.BrambillaS.UgoliniR.Pioli (2000) Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand101: 323–329.
    • (2000) Acta Psychiatr Scand , vol.101 , pp. 323-329
    • Morosini, P.1    Magliano, L.2    Brambilla, L.3    Ugolini, S.4    Pioli, R.5
  • 74
    • 0033395494 scopus 로고    scopus 로고
    • Latent structures underlying schizophrenic symptoms: a five-dimensional model
    • M.NakayaH.SuwaK.Ohmori (1999) Latent structures underlying schizophrenic symptoms: a five-dimensional model. Schizophr Res39: 39–50.
    • (1999) Schizophr Res , vol.39 , pp. 39-50
    • Nakaya, M.1    Suwa, H.2    Ohmori, K.3
  • 75
    • 69949087539 scopus 로고    scopus 로고
    • Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials
    • J.NelsonG.Papakostas (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry166: 980–991.
    • (2009) Am J Psychiatry , vol.166 , pp. 980-991
    • Nelson, J.1    Papakostas, G.2
  • 76
    • 34347336444 scopus 로고    scopus 로고
    • Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third generation antipsychotics
    • A.Newman-TancrediD.CussacR.Depoortere (2007) Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third generation antipsychotics. Curr Opin Investig Drugs8: 539–554.
    • (2007) Curr Opin Investig Drugs , vol.8 , pp. 539-554
    • Newman-Tancredi, A.1    Cussac, D.2    Depoortere, R.3
  • 77
    • 79961166634 scopus 로고    scopus 로고
    • Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
    • A.Newman-TancrediM.Kleven (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl)216: 451–473.
    • (2011) Psychopharmacology (Berl) , vol.216 , pp. 451-473
    • Newman-Tancredi, A.1    Kleven, M.2
  • 78
    • 84857134134 scopus 로고    scopus 로고
    • Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease
    • T.NiitsuM.IyoK.Hashimoo (2012) Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease. Curr Pharm Des18: 875–883.
    • (2012) Curr Pharm Des , vol.18 , pp. 875-883
    • Niitsu, T.1    Iyo, M.2    Hashimoo, K.3
  • 79
    • 49749117054 scopus 로고    scopus 로고
    • Potentiation of nerve growth factor induced neurite outgrowth by fluvoxamine: role of sigma-1receptors, IP3 receptors and cellular signaling pathways
    • T.NishimuraT.IshimaM.IyoK.Hashimoto (2008) Potentiation of nerve growth factor induced neurite outgrowth by fluvoxamine: role of sigma-1receptors, IP3 receptors and cellular signaling pathways. PLoS ONE3: e2558.
    • (2008) PLoS ONE , vol.3 , pp. 2558
    • Nishimura, T.1    Ishima, T.2    Iyo, M.3    Hashimoto, K.4
  • 81
    • 84908428543 scopus 로고    scopus 로고
    • Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization
    • C.OosterhofM.MansariP.Blier (2014) Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther351: 585–595.
    • (2014) J Pharmacol Exp Ther , vol.351 , pp. 585-595
    • Oosterhof, C.1    Mansari, M.2    Blier, P.3
  • 82
    • 84863393105 scopus 로고    scopus 로고
    • The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults
    • K.PosnerG.BrownB.StanleyD.BrentK.YershovaM.Oquendo (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry168: 1266–1277.
    • (2011) Am J Psychiatry , vol.168 , pp. 1266-1277
    • Posner, K.1    Brown, G.2    Stanley, B.3    Brent, D.4    Yershova, K.5    Oquendo, M.6
  • 83
    • 84884489165 scopus 로고    scopus 로고
    • Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole
    • S.PotkinA.RaoufiniaS.MallikaarjunP.BricmontT.Peters-StricklandW.Kasper. (2013) Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin29: 1241–1251.
    • (2013) Curr Med Res Opin , vol.29 , pp. 1241-1251
    • Potkin, S.1    Raoufinia, A.2    Mallikaarjun, S.3    Bricmont, P.4    Peters-Strickland, T.5    Kasper, W.6
  • 84
    • 4644271084 scopus 로고    scopus 로고
    • Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
    • B.RothD.ShefflerW.Kroeze (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov3: 353–359.
    • (2004) Nat Rev Drug Discov , vol.3 , pp. 353-359
    • Roth, B.1    Sheffler, D.2    Kroeze, W.3
  • 85
    • 84555186903 scopus 로고    scopus 로고
    • Second-generation antipsychotic drugs and extra pyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons
    • C.Rummel-KlugeK.KomossaS.SchwarzH.HungerF.SchmidW.Kissling. (2012) Second-generation antipsychotic drugs and extra pyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull38: 167–177.
    • (2012) Schizophr Bull , vol.38 , pp. 167-177
    • Rummel-Kluge, C.1    Komossa, K.2    Schwarz, S.3    Hunger, H.4    Schmid, F.5    Kissling, W.6
  • 86
    • 84883815411 scopus 로고    scopus 로고
    • Pharmacological characterization of a structurally novel a2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models
    • J.SallinenJ.HolappaA.KoivistoK.KuokkanenH.ChapmanJ.Lehtimäki. (2013) Pharmacological characterization of a structurally novel a2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol113: 239–249.
    • (2013) Basic Clin Pharmacol Toxicol , vol.113 , pp. 239-249
    • Sallinen, J.1    Holappa, J.2    Koivisto, A.3    Kuokkanen, K.4    Chapman, H.5    Lehtimäki, J.6
  • 87
    • 0014723449 scopus 로고
    • A rating scale for extra pyramidal side effects
    • G.SimpsonJ.Angus (1970) A rating scale for extra pyramidal side effects. Acta Psychiatr Scand Suppl212: 11–19.
    • (1970) Acta Psychiatr Scand Suppl , vol.212 , pp. 11-19
    • Simpson, G.1    Angus, J.2
  • 88
    • 76749163673 scopus 로고    scopus 로고
    • Attenuation of phencyclidine induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine (2A) receptor inverse agonist
    • S.SnigdhaM.HoriguchiM.HuangZ.LiM.ShahidJ.Neill. (2010) Attenuation of phencyclidine induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine (2A) receptor inverse agonist. J Pharmacol Exp Ther332: 622–631.
    • (2010) J Pharmacol Exp Ther , vol.332 , pp. 622-631
    • Snigdha, S.1    Horiguchi, M.2    Huang, M.3    Li, Z.4    Shahid, M.5    Neill, J.6
  • 89
    • 0027887319 scopus 로고
    • Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
    • C.StockmeierJ.DiCarloY.ZhangP.ThompsonH.Meltzer (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther266: 1374–1384.
    • (1993) J Pharmacol Exp Ther , vol.266 , pp. 1374-1384
    • Stockmeier, C.1    DiCarlo, J.2    Zhang, Y.3    Thompson, P.4    Meltzer, H.5
  • 90
    • 0034810016 scopus 로고    scopus 로고
    • Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
    • T.SumiyoshiM.MatsuiS.NoharaI.YamashitaM.KurachiC.Sumiyoshi. (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry158: 1722–1725.
    • (2001) Am J Psychiatry , vol.158 , pp. 1722-1725
    • Sumiyoshi, T.1    Matsui, M.2    Nohara, S.3    Yamashita, I.4    Kurachi, M.5    Sumiyoshi, C.6
  • 92
    • 84938735906 scopus 로고    scopus 로고
    • Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results of two pivotal clinical studies
    • M.ThaseJ.YouakimA.SkubanM.HobartP.ZhangS.Legacy. (2014). Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results of two pivotal clinical studies. Neuropsychopharmacology39: S357.
    • (2014) Neuropsychopharmacology , vol.39 , pp. 357
    • Thase, M.1    Youakim, J.2    Skuban, A.3    Hobart, M.4    Zhang, P.5    Legacy, S.6
  • 93
    • 84942502416 scopus 로고    scopus 로고
    • Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants
    • M.ThaseJ.YouakimA.SkubanM.HobartC.AugustineP.Zhang. (2015a) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry76: 1224–1231.
    • (2015) J Clin Psychiatry , vol.76 , pp. 1224-1231
    • Thase, M.1    Youakim, J.2    Skuban, A.3    Hobart, M.4    Augustine, C.5    Zhang, P.6
  • 94
    • 84942502726 scopus 로고    scopus 로고
    • Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study
    • M.ThaseJ.YouakimA.SkubanM.HobartP.ZhangR.McQuade. (2015b) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry76: 1232–1240.
    • (2015) J Clin Psychiatry , vol.76 , pp. 1232-1240
    • Thase, M.1    Youakim, J.2    Skuban, A.3    Hobart, M.4    Zhang, P.5    McQuade, R.6
  • 95
    • 85174274604 scopus 로고    scopus 로고
    • accessed 2 October 2015,,. :
    • US FDA (2015) Drugs. Available at: http://www.fda.gov/Drugs/default.htm (accessed 2 October 2015).
    • (2015) Drugs
  • 97
    • 33745355536 scopus 로고    scopus 로고
    • The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model
    • M.Van der GaagT.HoffmanM.RemijsenR.HijmanL.de HaanB.van Meijel. (2006) The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res85: 280–287.
    • (2006) Schizophr Res , vol.85 , pp. 280-287
    • Van der Gaag, M.1    Hoffman, T.2    Remijsen, M.3    Hijman, R.4    de Haan, L.5    van Meijel, B.6
  • 98
    • 0142226998 scopus 로고    scopus 로고
    • Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors
    • A.VillegierG.BlancJ.GlowinskiJ.Tassin (2003) Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. Pharmacol Biochem Behav76: 267–274.
    • (2003) Pharmacol Biochem Behav , vol.76 , pp. 267-274
    • Villegier, A.1    Blanc, G.2    Glowinski, J.3    Tassin, J.4
  • 99
    • 0028945429 scopus 로고
    • Principal components and further possibilities with the PANSS
    • L.Von KnorringE.Lindstrom (1995) Principal components and further possibilities with the PANSS. Acta Psychiatr Scand Suppl388: 5–10.
    • (1995) Acta Psychiatr Scand Suppl , vol.388 , pp. 5-10
    • Von Knorring, L.1    Lindstrom, E.2
  • 100
    • 38049040370 scopus 로고    scopus 로고
    • Multi and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges
    • E.WongS.NikamM.Shahid (2008) Multi and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs9: 28–36.
    • (2008) Curr Opin Investig Drugs , vol.9 , pp. 28-36
    • Wong, E.1    Nikam, S.2    Shahid, M.3
  • 101
    • 0035983682 scopus 로고    scopus 로고
    • Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride
    • F.YokoiG.GründerK.BiziereM.StephaneA.DoganR.Dannals. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology27: 248–259.
    • (2002) Neuropsychopharmacology , vol.27 , pp. 248-259
    • Yokoi, F.1    Gründer, G.2    Biziere, K.3    Stephane, M.4    Dogan, A.5    Dannals, R.6
  • 102
    • 84903988963 scopus 로고    scopus 로고
    • Effects of brexpiprazole, a novel serotonin–dopamine activity modulator, on phencyclidine induced cognitive deficits in mice: a role for serotonin5-HT1A receptors
    • N.YoshimiY.FujitaY.OhgiT.FutamuraT.KikuchiK.Hashimoto (2014) Effects of brexpiprazole, a novel serotonin–dopamine activity modulator, on phencyclidine induced cognitive deficits in mice: a role for serotonin5-HT1A receptors. Pharmacol Biochem Behav124: 245–249.
    • (2014) Pharmacol Biochem Behav , vol.124 , pp. 245-249
    • Yoshimi, N.1    Fujita, Y.2    Ohgi, Y.3    Futamura, T.4    Kikuchi, T.5    Hashimoto, K.6
  • 103
    • 84925944263 scopus 로고    scopus 로고
    • Improvement of dizocilpine induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator
    • N.YoshimiT.FutamuraK.Hashimoto (2015) Improvement of dizocilpine induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator. Eur Neuropsychopharm25: 356–364.
    • (2015) Eur Neuropsychopharm , vol.25 , pp. 356-364
    • Yoshimi, N.1    Futamura, T.2    Hashimoto, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.